- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04575363
RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer (PaCaBioMarkeR)
RPSA as a Potential Prognostic Biomarker of PDAC
PDAC (Pancreatic ductal adenocarcinoma) represents 90% of pancreatic tumors. The prognosis of PDAC remains poor at this time. Its management is based on surgery for early stages, associated with neoadjuvant and adjuvant chemotherapy. However, around 80% of patients will relapse after surgery. There is a lack of efficient biological biomarkers of PDAC, especially for prognosis. To date, CA19-9 is commonly used despite its lack of sensitivity and specificity.
Ribosomal protein SA (RPSA) is a transmembrane receptor localized at the cell surface but also in the cytosolic and nuclear regions. RPSA interacts with many proteins in the extracellular matrix (ECM), including laminin-1 and elastin. RPSA in involved in different cellular functions such as cell adhesion, migration, proliferation and differentiation. The expression of RPSA is increased in many cancers including breast, lung, prostate, pancreatic, etc. It could represent a molecular biomarker of tumor invasion and metastatic abilities. Moreover, the concentration of RPSA could be measured in the serum of patients with PDAC. Recent data suggest that a modification of the RPSA concentration could be a prognostic biomarker of PDAC.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jean-Baptiste OUDART
- Phone Number: 0033 03 10 73 62 87
- Email: joudart@chu-reims.fr
Study Locations
-
-
-
Reims, France
- Recruiting
- Damien JOLLY
-
Contact:
- Jean-Baptiste OUDART
- Phone Number: 03 10 73 62 87
- Email: joudart@chu-reims.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
inclusion criteria :
- Patients treated at the Reims University Hospital for a resectable or potentially resectable pancreatic tumor, with or without neoadjuvant chemotherapy
- Adults (aged more than 18 years old)
- Patients who have signed the informed consent form
exclusion criteria :
- Patients with a prior history of cancer (excluding basal cell carcinoma or in situ cervical cancer that received conventional cancer treatment).
- Minors
- Patients for whom PDAC is not the retained diagnosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pancreatic adenocarcinoma patient
patient with pancreatic ductal adenocarcinoma
|
Blood sample
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RPSA serum concentration
Time Frame: Day 0
|
The RPSA serum concentration is assessed with commercially available RPSA ELISA assay (MyBioSource - MBS9137288).
|
Day 0
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PA20113
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Ductal Adenocarcinoma (PDAC)
-
Mayo ClinicRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | PDAC | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
Dana-Farber Cancer InstituteRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Neoplasm | PDAC | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
Tianjin Medical University Cancer Institute and...Not yet recruitingPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRecruitingPDAC - Pancreatic Ductal AdenocarcinomaChina
-
Qilu Pharmaceutical Co., Ltd.Not yet recruitingPancreatic Ductal Adenocarcinoma (PDAC)China
-
Azienda Ospedaliera Universitaria Integrata VeronaRecruitingPDAC - Pancreatic Ductal AdenocarcinomaItaly
-
Cedars-Sinai Medical CenterRecruitingPDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
Qilu Hospital of Shandong UniversityCompletedPancreatic Ductal Adenocarcinoma (PDAC)China
-
Ruijin HospitalRecruitingPancreatic Ductal Adenocarcinoma, PDACChina
-
Ruijin HospitalRecruitingPancreatic Ductal Adenocarcinoma, PDACChina
Clinical Trials on Blood sample
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
First Affiliated Hospital of Zhejiang UniversityRecruitingComplication | Hematologic Malignancy | Hematopoietic Stem Cell Transplantation | Chronic Graft-versus-host-diseaseChina
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceRecruitingImmune Thrombocytopenia | Autoimmune Hemolytic Anemia | Autoimmune NeutropeniaFrance
-
University Hospital, ToursCompletedMetastatic Prostate Cancer | Circulating Tumor DNAFrance
-
University Hospital, BordeauxActive, not recruitingSystemic Lupus Erythematosus | Systemic SclerodermaFrance
-
University Hospital, BordeauxCompletedRenal Function Disorder | Chronic Renal Diseases
-
Meir Medical CenterCompleted
-
University Hospital, ToursNot yet recruitingRenal Transplant | ConversionFrance